scispace - formally typeset
Y

Yongchang Zheng

Researcher at Peking Union Medical College Hospital

Publications -  64
Citations -  1072

Yongchang Zheng is an academic researcher from Peking Union Medical College Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 50 publications receiving 612 citations. Previous affiliations of Yongchang Zheng include Peking Union Medical College.

Papers
More filters
Journal ArticleDOI

Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma.

TL;DR: The proposed ceRNA network may help elucidate the regulatory mechanism by which lncRNAs function as ceRNAs and contribute to the pathogenesis of HCC.
Journal ArticleDOI

Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure.

TL;DR: The results indicated that 3DP-HO model of liver tissues possessed in vivo hepatic functions and alleviated liver failure after transplantation, suggesting that 3D bioprinting could be used to generate human liver tissues as the alternative transplantation donors for treatment of liver diseases.
Journal ArticleDOI

DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.

TL;DR: The results obtained by integrating multidimensional genomic data offer novel research directions for HCC biomarkers and new possibilities for individualized treatment of patients with HCC.
Journal ArticleDOI

Local statistics and non-local mean filter for speckle noise reduction in medical ultrasound image

TL;DR: This study combines local statistics with the NLM filter to reduce speckle in ultrasound images and demonstrates that the proposed method outperforms the original NLM, as well as many previously developed methods.
Journal ArticleDOI

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

TL;DR: The signaling pathway underlying the dysregulation of PD-1/PD-L in tumors is reviewed, the current clinical data for PD- 1/ PD-L inhibitors in GI malignancies are summarized, and the road toward precision immunotherapy in relation to PD-2/2/3 blockade is discussed.